Protein expression analysis

Antibody efficacy evaluation

·

·Blue arrows: time for sensitization and challenge; 

·Red arrows: time for drug administration.

Antibody efficacy evaluation

The proportion of BALF immune cells in acute mouse asthma model

Antibody efficacy evaluation

The number of BALF immune cells in acute mouse asthma model

BALF immune cell profiles in acute mouse asthma model

BALF Immune cells were isolated from B-hIL33 mice (n=5). The number of eosinophils were deterimined by flow cytometry in acute asthma mice treated with or without etokimab anolog. Treatment of etokimab analog almost completely abolished the inflammatory cells in homozygous B-hIL33 mice as opposed to in untreated mice.

Antibody efficacy evaluation

IgE production in mouse asthma model

IgE production

Serum was collected at the study endpoint. IgE levels responded to OVA-specific antibody were analyzed. 

The results show that the levels of IgE in mice treated with etokimab is much lower than that in untreated mice. 

1.Gene expression: human IL33 was detectable in the homozygous B-hIL33 mice.
2.Protein expression: human IL33 was detectable in the homozygous B-hIL33 mice.
3.Analysis of leukocyte subpopulation: the expression profile of leukocytes subpopulation in homozygous B-hIL33 mice is similar to that in the C57BL/6 mice.
4.Antibody efficacy evaluation: OVA-induced acute asthma model has been successfully established as indicated by increased eosinophilia, IgE production. This model is further validated with etokimab, which greatly reduced the inflammatory cells and IgE.
5.B-hIL33 mice is a validated, valuable tool for in vivo efficacy evaluation of anti-human IL33 antibodies.